EU Approves Moderna's Combined COVID-19 and Flu Vaccine

• mCombriax is the first combined COVID and flu vaccine to receive regulatory approval anywhere in the world
• The vaccine is authorized for adults aged 50 and older, combining two seasonal vaccinations into a single dose
• Moderna's messenger RNA technology platform enables the combination vaccine approach

EU Approves Moderna's Combined COVID-19 and Flu Vaccine

The European Medicines Agency (EMA) on Friday, February 27, 2026, granted marketing authorization for Moderna's mCombriax, marking a significant milestone as the world's first combined messenger RNA (mRNA) vaccine targeting both COVID-19 and seasonal influenza in a single dose.

Key Details:

• Product Name: mCombriax
• Company: Moderna
• Target Population: Individuals aged 50 and older
• Technology: mRNA-based vaccine platform
• Approval Date: February 27, 2026
• Geographic Scope: European Union

Market Implications:

This regulatory approval represents a breakthrough in vaccine technology and positions Moderna as a leader in combination vaccine development. The dual-purpose vaccine addresses two significant respiratory disease threats simultaneously, potentially improving vaccination compliance among older adults who face higher risks from both illnesses.

The approval could provide Moderna with a competitive advantage in the European vaccine market, potentially generating new revenue streams as COVID-19 vaccine demand has declined from pandemic peaks. By combining two vaccines into one shot, mCombriax may reduce healthcare costs, improve patient convenience, and increase uptake rates among the target demographic.

This development demonstrates the versatility of mRNA technology beyond single-pathogen applications and could pave the way for additional combination vaccines. The approval may also influence global regulatory decisions, as other markets may follow the EU's lead.

For investors, this represents product diversification for Moderna as the company moves beyond standalone COVID-19 vaccines, potentially stabilizing long-term revenue prospects in an evolving post-pandemic landscape.